Inventiva Halts Enrollment in Phase 3 MASH Study Following Patient Raised Liver Enzyme Incident

Biotech company Inventiva has temporarily paused the enrollment of new patients in its ongoing phase 3 trial for its lead liver disease drug after a study participant exhibited elevated liver enzyme levels. This clinical hold is a precautionary measure to ensure patient safety as the company investigates the situation.

Inventiva's lead compound, lanifibranor, is currently undergoing clinical trials primarily for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a form of chronic liver disease. The decision to suspend enrollment is consistent with clinical trial protocols, which often involve pauses or holds when safety concerns arise.

This incident occurs while Inventiva is also presenting results and abstracts related to lanifibranor at the upcoming The Liver Meeting® 2023. The company has previously discussed the therapeutic potential of lanifibranor for various liver diseases, including fatty liver and NASH (Non-alcoholic steatohepatitis), and continues to advance its clinical development plan for this promising compound.